Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Part of paid clinical trials in Los Angeles, California.

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT04712851
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cervical Intraepithelial Neoplasia
  • Cervical Squamous Cell Carcinoma In Situ
  • Cervical Squamous Intraepithelial Neoplasia 2

Eligibility Criteria

Sex
FEMALE
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — BIOLOGICAL
    Given IV

Study Details

This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date
Jun 30, 2021
Status verified
Mar 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2028

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (pembrolizumab)
    Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 4 cycles (24 weeks).

Primary Outcome Measure

Pathological response rate [ Time Frame: At 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California at Los Angeles / Jonsson Comprehensive Cancer CenterLos AngelesCalifornia90095
Maria Garcia-Jimenez, MD
[email protected]
310-209-0618
Rosleen Mala
[email protected]
310 794-3879
John A. Glaspy, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
University of California at Los Angeles / Jonsson Comprehensive Cancer Center· Los Angeles, CA

Related Studies